09.12.2015
WILEX AG DE000A11QVV0
DGAP-News: WILEX AG: WILEX AG successfully completes capital increases
DGAP-News: WILEX AG / Key word(s): Capital Increase
WILEX AG: WILEX AG successfully completes capital increases
09.12.2015 / 14:09
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
PRESS RELEASE
WILEX AG successfully completes capital increases
- Cash capital increase of around 10% using authorised capital completed
with dievini (private placement excluding shareholders' subscription
rights)
- Rights issue fully subscribed
Munich, 9 December 2015 - The Executive Management Board of WILEX AG (ISIN
DE000A11QVV0 / WL6 / FSE) today decided - with the Supervisory Board's
approval - to set the final scope of the rights issue to be executed to a
total of 443,124 New Shares. Prior to the rights issue, a private placement
was carried out with the main shareholder, dievini Hopp BioTech holding
GmbH & Co. KG (dievini).
Private placement excluding shareholders' subscription rights
dievini acquired all 930,560 new no par value bearer shares from the first
capital measure at an issue price of EUR 1.84. Once this capital increase
has been entered in the Commercial Register, this will lift the Company's
share capital by around 10%, from EUR 9,305,608.00 to EUR 10,236,168.00.
Capital increase using authorised capital with subscription rights
In addition, WILEX's shareholders exercised their subscription and
additional subscription rights for all 443,124 new no par value bearer
shares at a price of EUR 1.84 per share by the end of the subscription
period on 8 December 2015. Shareholders exercised subscription rights for a
total of 184,419 New Shares. This meant that 258,705 New Shares were
available for additional subscription by shareholders, which were allocated
in full to the shareholders through their custodian banks in connection
with the capital increase. Accordingly, this second capital increase will
lift the Company's share capital by EUR 443,124.00, from EUR 10,236,168.00
to EUR 10,679,292.00, once its execution has been entered in the Commercial
Register.
WILEX AG plans to use the total gross issue proceeds of EUR 2.5 million
from both capital increases to finance the further development of its own
ADC technology (Antibody Targeted Amanitin Conjugates - ATACs). The main
objective is to optimize a PSMA antibody drug conjugate as the first
proprietary ATAC candidate and make this ready for early clinical
development. In addition to preclinical investigations, this will entail
establishing the manufacturing process for the PSMA antibody, the amanitin
drug and the antibody drug conjugate at subcontractors in accordance with
GMP standards.
Following the entry of the execution of both capital measures in the
Commercial Register, which is scheduled to take place within the next few
days, the total number of WILEX shares issued will increase to 10,679,292.
The subscribed and allotted shares are expected to be delivered on 15
December 2015, but no earlier than after their admission to trading on the
Regulated Market (Prime Standard). The new shares are due to be included in
trading on 15 December 2015. All new shares carry dividend rights from 1
December 2015. Given this difference in dividend rights, the new shares
will be traded separately under the ISIN DE000A169P97 / WKN A16 9P9 until
the planned inclusion in the Company's current listing, which will take
place after the Annual General Meeting adopting resolutions regarding the
2014/2015 financial year. ODDO SEYDLER BANK AG, Frankfurt, was the sole
lead manager of the capital measures.
About WILEX
WILEX AG is a biopharmaceutical company which discontinued all clinical
development activities at its Munich site and now exercises a holding
function as the Group parent. Research and development focus on the
operations of its subsidiary Heidelberg Pharma GmbH in Ladenburg, which
primarily advances the development of the innovative platform technology
for antibody drug conjugates (ADC technology) and provides pre-clinical
drug discovery and development services. WILEX has the diagnostic and
therapeutic drug candidates REDECTANE(R) and RENCAREX(R), which are
available for out-licensing and further development in Phase III for
external partners. WILEX is listed at the Frankfurt Stock Exchange: ISIN
DE000A11QVV0 / WKN A11QVV / Symbol WL6. More information is available at
http://www.wilex.com/.
Contact IR/PR support WILEX AG MC Services AG Corporate Communications Katja Arnold (CIRO) Sylvia Wimmer Executive Director & Partner Tel.: +49 (0)89-41 31 38-29 Tel.: +49 (0)89-210 228-40 Email: investors[at]wilex.com Mobile: +49 (0)160 9360 3022 Grillparzerstr. 18, 81675 Munich Email: katja.arnold[at]mc-services.euThis communication contains certain forward-looking statements relating to the Company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "will", "should", "future", "potential" or similar expressions or by a general discussion of the Company's strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial position, earnings, achievements, or industry results, to be materially different from any future results, earnings or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments. --------------------------------------------------------------------------- 09.12.2015 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: WILEX AG Grillparzerstr. 18 81675 München Germany Phone: +49 (0)89 41 31 38 - 0 Fax: +49 (0)89 41 31 38 - 99 E-mail: [email protected] Internet: www.wilex.com ISIN: DE000A11QVV0 WKN: A11QVV Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart End of News DGAP News Service --------------------------------------------------------------------------- 422395 09.12.2015
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
WILEX AG ISIN: DE000A11QVV0 können Sie bei EQS abrufen
Biotechnologie , A11QVV , HPHA , XETR:WL6